Skip to Main Content
Chapter e1



Telavancin is the first approved lipoglycopeptide for the treatment of skin and soft-tissue infection due to resistant gram-positive bacterial pathogens. At the present time, skin and soft tissue infection is the only indication for this agent. Telavancin displays concentration-dependent bactericidal killing and a 7.5-h half-life and postantibiotic effect of 4-6 hours allowing for once-daily dosing. Taste disturbance, nausea, headache, foamy urine, and reversible kidney injury are the most commonly observed adverse events. Similar to daptomycin and linezolid, telavancin is useful in the treatment of resistant bacterial skin and soft-tissue infection and is an alternative for patients who are intolerant of vancomycin.

Saravolatz LD et al. Telavancin: a novel lipoglycopeptide. Clin Infect Dis. 2009 Dec 15;49(12):1908–14.   [PubMed: 19911938]

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.